BLATT LAWRENCE has filed 15 insider transactions across 1 company since March 2023.
Most recent transaction: a grant/award of 105840 shares of Aligos Therapeutics, Inc. ($ALGS) on March 09, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 9, 2026 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | President and CEO | A | Stock Option (Right to Buy) | 105840 | $0.00 | 105,840.0000 | 6,153,507 | 9999.99% | 1.72% |
| July 16, 2025 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | President and CEO | A | Stock Option (Right to Buy) | 179800 | $0.00 | 179,800.0000 | 3,864,436 | 9999.99% | 4.65% |
| Feb. 28, 2025 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | President and CEO | A | Stock Option (Right to Buy) | 140103 | $0.00 | 140,103.0000 | 3,864,436 | 9999.99% | 3.63% |
| Sept. 4, 2024 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Stock Option (Right to Buy) | 33920 | $0.00 | 33,920.0000 | 79,900,000 | 9999.99% | 0.04% |
| March 1, 2024 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Stock Option (Right to Buy) | 965435 | $0.00 | 965,435.0000 | 3,003,855 | 9999.99% | 32.14% |
| Feb. 27, 2024 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | D | Stock Option (Right to Buy) | 323400 | $0.00 | 0.0000 | 3,003,855 | 100.00% | 10.77% |
| Feb. 27, 2024 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | D | Stock Option (Right to Buy) | 80850 | $0.00 | 0.0000 | 3,003,855 | 100.00% | 2.69% |
| Feb. 28, 2024 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Stock Option (Right to Buy) | 132352 | $0.00 | 132,352.0000 | 3,003,855 | 9999.99% | 4.41% |
| Feb. 28, 2024 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Stock Option (Right to Buy) | 230999 | $0.00 | 230,999.0000 | 3,003,855 | 9999.99% | 7.69% |
| Feb. 27, 2024 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | D | Stock Option (Right to Buy) | 450000 | $0.00 | 0.0000 | 3,003,855 | 100.00% | 14.98% |
| Feb. 28, 2024 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Stock Option (Right to Buy) | 57749 | $0.00 | 57,749.0000 | 3,003,855 | 9999.99% | 1.92% |
| Oct. 25, 2023 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Warrants (Right to Buy) | 305138 | $0.13 | 305,138.0000 | 0 | 9999.99% | 0.00% |
| Oct. 25, 2023 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Common Stock | 610277 | $0.76 | 2,120,633.0000 | 0 | 40.41% | 0.00% |
| Sept. 8, 2023 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Stock Option (Right to Buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| March 15, 2023 | Aligos Therapeutics, Inc. | $ALGS | BLATT LAWRENCE | Chief Executive Officer | A | Stock Option (Right to Buy) | 242500 | $0.00 | 242,500.0000 | 0 | 9999.99% | 0.00% |